ATE369865T1 - Gerinnungshemmende zusammensetzung - Google Patents

Gerinnungshemmende zusammensetzung

Info

Publication number
ATE369865T1
ATE369865T1 AT03733728T AT03733728T ATE369865T1 AT E369865 T1 ATE369865 T1 AT E369865T1 AT 03733728 T AT03733728 T AT 03733728T AT 03733728 T AT03733728 T AT 03733728T AT E369865 T1 ATE369865 T1 AT E369865T1
Authority
AT
Austria
Prior art keywords
composition
tablet
heparin
polar lipids
anticolotting
Prior art date
Application number
AT03733728T
Other languages
English (en)
Inventor
Bengt Hersloef
Per Tingvall
Original Assignee
Ltp Lipid Technologies Provide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltp Lipid Technologies Provide filed Critical Ltp Lipid Technologies Provide
Application granted granted Critical
Publication of ATE369865T1 publication Critical patent/ATE369865T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT03733728T 2002-06-20 2003-06-12 Gerinnungshemmende zusammensetzung ATE369865T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201922A SE0201922D0 (sv) 2002-06-20 2002-06-20 Koagulationshindrande komposition (Anticoagulant Composition)

Publications (1)

Publication Number Publication Date
ATE369865T1 true ATE369865T1 (de) 2007-09-15

Family

ID=20288280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03733728T ATE369865T1 (de) 2002-06-20 2003-06-12 Gerinnungshemmende zusammensetzung

Country Status (10)

Country Link
US (1) US7202087B2 (de)
EP (1) EP1542705B8 (de)
AT (1) ATE369865T1 (de)
AU (1) AU2003239011A1 (de)
DE (1) DE60315676T2 (de)
DK (1) DK1542705T3 (de)
ES (1) ES2291645T3 (de)
PT (1) PT1542705E (de)
SE (1) SE0201922D0 (de)
WO (1) WO2004000332A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456327B2 (en) 2015-08-28 2019-10-29 Craig Robertson Package for frozen nutrient pill
WO2018185302A1 (en) * 2017-04-07 2018-10-11 Syddansk Universitet Moulding and casting of composites

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
CA2182577C (en) * 1994-02-04 2002-08-20 Anders Carlsson Lipophilic carrier preparations
GB9719182D0 (en) * 1997-09-09 1997-11-12 Boc Group Plc Guide wire introducer
SE0000730D0 (sv) * 2000-03-06 2000-03-06 Scotia Holdings Plc Lipid carrier
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
JP4116436B2 (ja) * 2000-12-14 2008-07-09 エフ．ホフマン−ラ ロシュ アーゲー 自己乳化脂質マトリックス（ｓｅｌｍ）
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning

Also Published As

Publication number Publication date
US20060165780A1 (en) 2006-07-27
DE60315676D1 (de) 2007-09-27
EP1542705B1 (de) 2007-08-15
EP1542705A1 (de) 2005-06-22
ES2291645T3 (es) 2008-03-01
DK1542705T3 (da) 2007-11-26
DE60315676T2 (de) 2008-06-05
AU2003239011A1 (en) 2004-01-06
WO2004000332A1 (en) 2003-12-31
EP1542705B8 (de) 2007-10-10
PT1542705E (pt) 2007-11-09
SE0201922D0 (sv) 2002-06-20
US7202087B2 (en) 2007-04-10

Similar Documents

Publication Publication Date Title
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
BR0312427A (pt) Combinação, uso de uma combinação, método para a produção de um efeito inibitório de ibat em um animal de sangue quente, método de prevenção de diarréia, composição farmacêutica, método de tratamento de condições hiperlipidêmicas em um animal de sangue quente, e, uso de um sal metálico
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
PL343904A1 (en) Compounds and methods for the inhibition of the expression of vcam-1
DK1576970T3 (da) Intraluminal indretning med en coating, der indeholder et terapeutisk middel
ES2191070T3 (es) Arilalquil-piridazinonas.
MXPA05012570A (es) Derivados de tetrahidroisoquinolina como activadores de ppar-a.
ZA202210079B (en) Compositions and methods for treating or preventing inflammatory diseases including diabetes mellitus 10 type i and type ii and thyroid diseases
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE60327511D1 (de) Zusammensetzung zur oralen oder rektalen verabreichung
ECSP055844A (es) Nuevos compuestos triciclicos
WO2003059875A3 (en) DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
NL300198I2 (nl) Toepassing van 2-(2-nitro-4-trifluormethylbenzoyl)cyclohexaandion-1,3 voor het behandelen van tyrosinemie, alsmede farmaceutische preparaten.
ATE488226T1 (de) Mahonia aquifolium extrakt, extraktionsverfahren und diesen enthaltende pharmazeutische zusammensetzung
ATE369865T1 (de) Gerinnungshemmende zusammensetzung
UY26895A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
PT746551E (pt) Acidos 4-aril-2-hidroxitetronicos opticamente puros
MY140954A (en) Composition for oral or rectal administration
DE602005010256D1 (de) Produkt pflanzlichen ursprungs, das proanthocyane enthält, sowie verfahren zu seiner herstellung
ATE355287T1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
ECSP951559A (es) Inhibidores de la 5- lipoxigenasa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1542705

Country of ref document: EP

REN Ceased due to non-payment of the annual fee